एमियोडेरोन और लैपाटिनिब का इंटरैक्शन

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy.

Avoid strong CYP3A4 inhibitors.

If unavoidable, consider dose reduction of TYKERB in patients coadministered a strong CYP3A4 inhibitor.

TYKERB may prolong the QT interval in some patients.

Ketoconazole : In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.